VRCA Live signaler | Maksimer profitt med Getagraph.com

KJøP 110335 min ago

@ $5.55

Utstedt: 13 feb 2024 @ 16:00

Avkastning: 28.94%

Forrige signal: feb 9 - 17:12

Forrige signal: Selg

Avkastning: 2.31 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States...

Stats
Dagens volum	342 411
Gjennomsnittsvolum	137 296
Markedsverdi	303.30M
EPS	$0 ( 2024-02-29 )
Neste inntjeningsdato	( $-0.530 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.83
ATR14	$0.0230 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Hayes Christopher G.	Buy	40 000	Common Stock
2024-03-15	Hayes Christopher G.	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Goldenberg Gary	Buy	40 000	Common Stock
2024-03-15	Goldenberg Gary	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Kohler Terry	Buy	80 000	Employee Stock Option (right to buy)

INSIDER POWER
90.97
Last 98 transactions
Buy: 14 420 498 \| Sell: 288 608

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: -0.77 (moderate negative)

Signal:(71.027) Neutral

Verrica Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
TGTX	0.959
IDCC	0.956
SLMBP	0.955
VBOCU	0.955
RAM	0.95
WKEY	0.95
OVLY	0.948
NCAC	0.947
MESA	0.946
GPACU	0.945

10 Mest negative korrelasjoner
CBNK	-0.945
CYTO	-0.939
GSMG	-0.938
GNTY	-0.936
BFRI	-0.936
FGBI	-0.936
GOOD	-0.934
AMNB	-0.93
CMLS	-0.929
ALHC	-0.927

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Verrica Pharmaceuticals Korrelasjon - Valuta/Råvare

0.22
( neutral )

0.47
( neutral )

0.00
( neutral )

0.11
( neutral )

0.13
( neutral )

Verrica Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$5.12M
Bruttogevinst:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2023
Omsetning:	$5.12M
Bruttogevinst:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2022
Omsetning:	$9.03M
Bruttogevinst:	$8.31M (91.97 %)
EPS:	$-0.810

FY	2021
Omsetning:	$12.00M
Bruttogevinst:	$12.00M (100.00 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.